艰难梭菌对万古霉素敏感性降低与初始治愈率及持续临床应答率降低相关
这项多中心队列研究纳入2016至2021年接受口服万古霉素治疗的成人艰难梭菌感染患者,采用琼脂稀释法检测万古霉素敏感性。34%的分离株敏感性降低,其30天持续临床应答率低于敏感株(76% vs 86%,P=0.031),14天初始治愈率亦较低(89% vs 96%,P=0.04),多变量模型中敏感性降低为30天持续临床应答的独立预测因素(OR 0.52,95%CI 0.28-0.97,P=0.04)。
要点
- 34%(102/300)的艰难梭菌分离株对万古霉素敏感性降低(MIC>2 μg/mL)。
- 敏感性降低组30天持续临床应答率76%,低于敏感组的86%(P=0.031)。
- 敏感性降低组14天初始治愈率89%,低于敏感组的96%(P=0.04)。
核心结论
- 在研究的患者队列中,艰难梭菌对万古霉素敏感性降低与30天持续临床应答的 odds 降低及14天初始治愈率降低相关。
研究设计与样本
- 多中心队列研究,纳入2016至2021年接受口服万古霉素治疗的成人艰难梭菌感染患者,共300株分离株。
- 分离株行琼脂稀释法万古霉素敏感性检测、核糖体分型及 vanR 基因 Sanger 测序;敏感性降低定义为万古霉素 MIC>2 μg/mL。
主要发现
- 34%(102/300)的分离株万古霉素敏感性降低(范围0.5-16 μg/mL;MIC50/90=2/4 μg/mL)。
- 核糖体型027在敏感性降低分离株中占比最高(77.4%,41/53)。
- 总体83%(249例)患者达到30天持续临床应答;敏感性降低组为76%(78/102),敏感组为86%(171/198),P=0.031。
- 敏感性降低组14天初始治愈率为89%,敏感组为96%,P=0.04。
- 多变量模型中敏感性降低为30天持续临床应答的独立预测因素(OR 0.52,95%CI 0.28-0.97,P=0.04)。
关键数值与推荐
- 万古霉素敏感性降低定义为 MIC>2 μg/mL。
- 主要结局为30天持续临床应答;次要结局为14天初始治愈、30天复发和30天死亡。
- 探索性分析评估 VanR Thr115Ala 多态性、敏感性与结局之间的关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epidemiologic studies have shown decreasing vancomycin susceptibility among clinical Clostridioides difficile isolates, but the impact on patient outcomes is unknown. We hypothesized that reduced vancomycin susceptibility would be associated with decreased rates of sustained clinical response (SCR). METHODS: This multicenter cohort study included adults with C. difficile infection (CDI) treated with oral vancomycin between 2016 and 2021. Clostridioides difficile isolates underwent agar dilution vancomycin susceptibility testing, ribotyping, and Sanger sequencing of the vancomycin resistance vanR gene. Reduced susceptibility was defined as vancomycin minimum inhibitory concentration (MIC) >2 μg/mL. The primary outcome was 30-day SCR; secondary outcomes were 14-day initial cure, 30-day recurrence, and 30-day mortality. Exploratory analysis assessed the association between the VanR Thr115Ala polymorphism, susceptibility, and outcomes. RESULTS: A high proportion (34% [102/300]) of C. difficile isolates exhibited reduced vancomycin susceptibility (range, 0.5-16 μg/mL; MIC50/90 = 2/4 μg/mL). Ribotype 027 accounted for the highest proportion (77.4% [41/53]) of isolates with reduced vancomycin susceptibility. Overall, 83% (249) of patients achieved 30-day SCR. Reduced vancomycin susceptibility was associated with lower rates of 30-day SCR (76% [78/102]) than vancomycin-susceptible strains (86% [171/198]; P = .031). A significantly lower rate of 14-day initial cure was also observed among individuals infected with strains with reduced vancomycin susceptibility (89% vs 96%; P = .04). Reduced susceptibility remained an independent predictor of 30-day SCR in multivariable modeling (odds ratio, 0.52 [95% confidence interval, .28-.97]; P = .04). CONCLUSIONS: Reduced vancomycin susceptibility in C. difficile was associated with decreased odds of 30-day SCR and lower 14-day initial cure rates in the studied patient cohort.
引用
- Eubank TA, Dureja C, Garey KW, et al. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024. PMID: 38382090. doi:10.1093/cid/ciae087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。